J&J Bets Big On Arrowhead’s Early Promise In Hepatitis B
The pharma is paying $250m up front for worldwide rights to Arrowhead’s Phase I/II RNAi candidate. Arrowhead says letting J&J take the lead on HBV enables it to focus on other pipeline programs it can bring to market itself.
You may also be interested in...
Arrowhead Eager To Take On ‘Straightforward’ NASH Approach Abandoned By J&J
J&J pipeline review results in return of PNPLA3-targeted NASH candidate optioned under 2018 alliance, but the fate of a hepatitis B candidate included in that deal is undetermined so far.
Big Pharma Pacts Benefit From Reduced HBV Biologics Competition
Partnerships between big pharma and biotech focused on biologic therapies for hepatitis B could reap the benefit of less competition as lone biotechs, such as Aligos, discontinue their candidates.
Arrowhead Gets $120m From GSK For First-In-Class NASH RNAi Candidate
GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.